NEWS

A challenging stroke case

MicroVention announces FDA approval for neuro stent device

MicroVention® Announces FDA Approval For Neuro Stent Device

MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Premarket Approval (PMA) for the LVIS® and LVIS® Jr. stents for stent-assisted coil embolization of intracranial aneurysms. The LVIS® and LVIS® Jr. stents are the first and only stents PMA approved for stent-assisted coil embolization and only the second PMA approved device designed for intracranial aneurysm treatment.

Carotid blowout during attempted thrombectomy

Left MCA Sub occlusion

CONNECTA 2018 - Gathering INR experts from Latin America

Mid basilar aneurysm: Discover the treatment choice!

New study shows use of EMBOTRAP® device clot retriever during treatment...

ARISE II Clinical Trial Results Published in Stroke Journal  Gothenburg, Sweden – May 16, 2018 –EMBOTRAP® Device, a device designed to remove clots from the brain following an ischemic stroke, demonstrated high success rates in restoring blood flow and patients achieved high rates of functional independence, according to ARISE II (Analysis of Revascularization in Ischemic Stroke with EMBOTRAP® Device), a new clinical trial published in Stroke [Journal]. 

CERENOVUS receives FDA clearance for next generation stent retriever dev...

EMBOTRAP II Revascularization Device Captures and Removes Life-threatening Blood Clots, Rapidly Restores Blood Flow IRVINE, California, May 21, 2018 - CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EMBOTRAP II Revascularization Device, a next generation stent retriever used to capture and remove life-threatening blood clots from the brain following an ischemic stroke.

Viz.ai to present expanded data on ALADIN and new data on ADVANCE expand...

Breadth of ALADIN data to reinforce results in expanded scans across multiple centers Important research will highlight a potential use case for Viz.ai’s deep learning, artificial intelligence algorithms beyond acute ischemic stroke.